Weight-Loss Drugs Fuel Boom for Firms That Fill Syringes
Some contract drug manufacturers are investing billions of dollars to expand or build factories that fill the injection pens used to administer treatments like Novo Nordisk’s Wegovy.
Related Articles
Rise in Psychotherapy Use Exposes Access Inequities
New data revealed an increase in outpatient psychotherapy use but highlighted disparities in access among less advantaged groups.
Muscle-Building Supplements May Lead Young Men to Steroids
Analysis revealed muscle-building supplement users had higher odds of initiating anabolic-androgenic steroid use by the next survey wave than nonusers.
Treating Pain Without Opioid Analgesics: The Right Patient at the Right Time
Do you know how to manage acute and chronic pain conditions with nonopioid analgesic treatments? Listen to our expert, Dr Steven Stanos, to learn more.
Chronic Kidney Disease: Assessment and Management
Covering the assessment and management of chronic kidney disease, including pharmacotherapy
Why Do People Struggle to Prioritize Their Long-Term Health?
Simply promoting “prevention is better than cure” doesn’t lead to the adoption of preventive behaviors. Here’s why.
Expert Discusses the ‘Four Pillars of Acne Pathogenesis’
“The average number of acne products used per patient is 2.53, but that’s also the average number of copays,” Shanna Miranti said.
General Practitioners and Specialists: What’s a Fair Price?
Experts debated ways to transition from hospital-centered care to value-based, patient-focused models.
Left Ventricular Assist Device: Emergency Management
A summary of 2024 UK guidance on the management of emergencies in implantable left ventricular assist device recipients in transplant centres
LGBTQ+-Inclusive Language Missing in Acne Assessment
An analysis of patient-reported outcome measures used for acne revealed gaps in the use of LGBTQ+-inclusive language, highlighting barriers to equitable care and assessment.
Clinical Advances in MASH: A Guide to Managing Metabolic Dysfunction-Associated Steatohepatitis
The incidence of MASH is on the rise. Learn more about determining risk in your patients and the new and emerging therapies available.